CHF Solutions (NASDAQ:CHFS) Upgraded by Zacks Investment Research to “Hold”


Share on StockTwits

CHF Solutions (NASDAQ:CHFS) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued on Tuesday, Zacks.com reports.

According to Zacks, “CHF Solutions, Inc. is a medical device company which focused on commercializing the Aquadex FlexFlow (R) System. Its commercial product Aquadex system, is indicated for temporary ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and extended ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization. CHF Solutions Inc., formerly known as Sunshine Heart Inc., is headquartered in Minneapolis. “

Other equities analysts have also recently issued reports about the stock. Maxim Group reissued a “buy” rating on shares of CHF Solutions in a research report on Thursday, November 12th. ValuEngine raised shares of CHF Solutions from a “buy” rating to a “strong-buy” rating in a research report on Monday, November 2nd.

Shares of NASDAQ CHFS opened at $8.21 on Tuesday. CHF Solutions has a 12-month low of $5.80 and a 12-month high of $38.70. The company has a market cap of $22.46 million, a P/E ratio of -0.16 and a beta of 1.55. The stock has a fifty day moving average price of $7.43 and a 200 day moving average price of $3.29.

CHF Solutions (NASDAQ:CHFS) last announced its quarterly earnings results on Tuesday, November 10th. The company reported ($2.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.83) by ($0.25). The company had revenue of $1.90 million during the quarter. CHF Solutions had a negative net margin of 254.26% and a negative return on equity of 173.61%. As a group, equities analysts predict that CHF Solutions will post -1.23 earnings per share for the current fiscal year.

Several hedge funds have recently modified their holdings of CHFS. Triton Wealth Management PLLC bought a new position in shares of CHF Solutions during the third quarter worth about $28,000. LPL Financial LLC bought a new position in shares of CHF Solutions during the third quarter worth about $29,000. UBS Group AG lifted its position in shares of CHF Solutions by 50.4% during the second quarter. UBS Group AG now owns 91,086 shares of the company’s stock worth $44,000 after purchasing an additional 30,532 shares during the last quarter. Finally, Magnus Financial Group LLC bought a new position in CHF Solutions in the third quarter worth about $73,000. 65.06% of the stock is currently owned by institutional investors and hedge funds.

About CHF Solutions

CHF Solutions, Inc, a medical device company, focuses on developing, manufacturing, and commercializing devices used in ultrafiltration therapy. The company's commercial product is the Aquadex FlexFlow System, which is indicated for temporary ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization.

Read More: Trading based on a resistance level

Get a free copy of the Zacks research report on CHF Solutions (CHFS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for CHF Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CHF Solutions and related companies with MarketBeat.com's FREE daily email newsletter.